MARKET

CASI

CASI

CASI Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.275
+0.015
+1.19%
Opening 14:56 09/24 EDT
OPEN
1.270
PREV CLOSE
1.260
HIGH
1.290
LOW
1.220
VOLUME
1.70M
TURNOVER
--
52 WEEK HIGH
3.900
52 WEEK LOW
1.135
MARKET CAP
178.24M
P/E (TTM)
-3.0422
1D
5D
1M
3M
1Y
5Y
CASI Pharmaceuticals, Inc. To Participate In Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
and , /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. , Chief Medical Officer of CASI Pharmaceuti...
PR Newswire - PRF · 4d ago
Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026
/PRNewswire/ -- Recently, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense research and development activities opposing dangerous diseases have developed in the launch of new drugs, rising FDA ap...
PR Newswire - PRF · 08/24 12:45
60 Biggest Movers From Yesterday
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value of $2.26 billion.
Benzinga · 08/24 09:11
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 08/23 13:58
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 08/23 12:12
25 Stocks Moving in Monday's Pre-Market Session
Gainers
Benzinga · 08/23 11:00
Casi Pharmaceuticals Inc (CASI) Chairman and CEO Wei-wu He Bought $614,400 of Shares
GuruFocus News · 08/20 05:17
Upgrade: Analysts Just Made A Substantial Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts
Shareholders in CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) may be thrilled to learn that the analysts have just...
Simply Wall St. · 08/14 07:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CASI. Analyze the recent business situations of CASI Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CASI stock price target is 4.450 with a high estimate of 6.00 and a low estimate of 3.800.
EPS
Institutional Holdings
Institutions: 88
Institutional Holdings: 47.48M
% Owned: 33.96%
Shares Outstanding: 139.80M
TypeInstitutionsShares
Increased
14
2.61M
New
17
1.21M
Decreased
23
6.00M
Sold Out
34
4.22M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.80%
Pharmaceuticals & Medical Research
-0.84%
Key Executives
Chairman/Chief Executive Officer/Director
Wei-Wu He
President
Wei Zhang
Other
Alexander Zukiwski
Independent Director
James Huang
Independent Director
Franklin Salisbury
Independent Director
Rajesh Shrotriya
Independent Director
Y. Alexander Wu
Independent Director
Quan Zhou
No Data
About CASI
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

Webull offers kinds of CASI Pharmaceuticals Inc stock information, including NASDAQ:CASI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CASI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CASI stock methods without spending real money on the virtual paper trading platform.